Black Diamond Therapeutic Bolsa (NASDAQ: BDTX)

Black Diamond Therapeutic (NASDAQ:BDTX) Bolsa

BLACK DIAMOND THERAPEUTICS I

Black Diamond Therapeutic

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

TRAW

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutics Inc

OSTX

OS Therapies Says It Has Submitred Request For Regenerative Medicine Advanced Therapy Designation To US FDA For OST-HER2 In Prevention Of Metastases In Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) reported quarterly losses of $(1.79) per share which missed the analyst consensus estimate of $(1.43) by 25.17 percent. This is a 14.76 percent increase over losses of $(2.10) per share from the same period last year. The company reported quarterly sales of $37.41 million which beat the analyst consensus estimate of $32.41 million by 15.40 percent. This is a 66.84 percent increase over sales of $22.42 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

FCEL

FuelCell Energy Q2 EPS $(1.79) Misses $(1.43) Estimate, Sales $37.41M Beat $32.41M Estimate

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

Price Target

Analyst Ratings

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

Benchmark analyst Cody Acree maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Buy and raises the price target from $255 to $315.

AVGO

Benchmark Maintains Buy on Broadcom, Raises Price Target to $315

Crypto markets continue to slide on Friday morning, with mounting macroeconomic pressure and fallout from the rift between Elon Musk and Donald Trump adding to investor unease.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$103,741.51</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,483.50</td>
<td>-4.4%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$148.54</td>
<td>-2.2%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.15</td>
<td>-2.2%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1765</td>
<td>-6.4%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001237</td>
<td>-3.2%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin large transaction volume decreased by 3.6%, while Ethereum saw a 27.8% increase. ETH's daily active addresses remained relatively flat, BTC saw a 5.6% jump.</li>
<li>Coinglass data shows 218,488 traders were liquidated in the past 24 hours for $979.20 million. </li>
<li>SoSoValue data shows net outflows of $278.4 million into spot Bitcoin ETFs. Spot Ethereum ETFs saw net inflows of $11.26 million.</li>
</ul>
Trader Notes: CoinBureau co-founder and CEO Nic Puckrin <a href="https://x.com/nicrypto/status/1930829675086962729">said</a> markets are reacting sharply to the Musk–Trump fallout, adding that weekend volatility could intensify in the absence of liquidity with the Non-Farm Payrolls data due today.
More Crypto Online <a href="https://x.com/Morecryptoonl/status/1930916945240490364">noted</a> that Bitcoin's dip may serve to attract new buyers, while Crypto Jelle added historical context that the previous BTC bull cycles lasted 152 weeks. If history repeats, there could be one final push over the next 20 weeks.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The previous cycles both lasted exactly 152 weeks. If that pattern repeats, we have 20 weeks of bull market left. One last hurrah, send <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> higher. <a href="https://t.co/8R4uZAryWr">pic.twitter.com/8R4uZAryWr</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1930900117038530783?ref_src=twsrc%5Etfw">June 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ted Pillows <a href="https://x.com/TedPillows/status/1930918837832081444">observed</a> that Ethereum is holding range support well, targeting a move to $3,000. 
He also flagged a cup and handle pattern forming on Solana, suggesting a short-lived dip followed by a bullish reversal near the $140–$145 zone. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SOL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SOL</a> cup and handle pattern formation. &#x1f440; It got rejected from a major resistance level, and is now going through a correction. Network activity is still rising, so I expect this dip won&#39;t last long. I think a retest of $140-$145 followed by a reversal is highly likely. <a href="https://t.co/ZloDVKj1vv">pic.twitter.com/ZloDVKj1vv</a>
&mdash; Ted (@TedPillows) <a href="https://twitter.com/TedPillows/status/1930621100175528020?ref_src=twsrc%5Etfw">June 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1930786375126987190">highlighted</a> a crucial technical setup for Dogecoin, noting that price has returned to the apex of a symmetrical triangle bottoming pattern, a level to watch for either a bounce or breakdown.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45798988/could-bitcoin-plummet-to-90000-soon">Could Bitcoin Plummet To $90,000 Soon?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Extend Losses After Trump-Musk Fallout

Outlook
For fiscal 2025, the Company tightens its revenue guidance to £660m to £670m and expects to be at the higher end of this range. The Company also raises its Adjusted EBITDA guidance to between £180 million and £190 million. The club remains committed to, and in compliance with, both the Premier League's Profit and Sustainability Rules and UEFA's Financial Fair Play Regulations.

Guidance

General

MANU

Manchester United Tightens Its 2025 Revenue Guidance From £650M-£670M To £660M-£670M And Expects To Be At The Higher End Of This Range; Raises Its Adjusted EBITDA Guidance To Between £180M-£190M Up From Prior Guidance Of £145M-£160M

Needham analyst Laura Martin reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and maintains $84 price target.

Reiteration

Needham Reiterates Buy on Trade Desk, Maintains $84 Price Target

LULU: -23% &#x7C; <a href="https://www.benzinga.com//node/45803006">Lululemon Athletica shares are trading lower after the company cut its FY25 GAAP EPS guidance below estimates.</a>
&nbsp;
AVGO: -5% &#x7C; <a href="https://www.benzinga.com//node/45802886">Broadcom shares are trading lower following Q2 reported financial results.</a>
&nbsp;
TSLA: 6% &#x7C; <a href="https://www.benzinga.com//node/45807968">Trump Signals Truce With Elon Musk After Online Feud: 'It's Going Very Well, Never Done Better'</a>

LULU

TSLA

Market-Moving News for June 6th

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) with a Buy and maintains $6 price target.

ARTL

D. Boral Capital Maintains Buy on Artelo Biosciences, Maintains $6 Price Target

Needham analyst Ryan Koontz reiterates Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Buy and maintains $90 price target.

CIEN

Needham Reiterates Buy on Ciena, Maintains $90 Price Target

Phosphate and Potash Operations Outlook
Phosphate sales volumes for the second quarter of 2025 are expected to be 1.5-1.6 million tonnes, revised down from 1.7-1.9 million tonnes. 2025 full year production volume is now expected to be 7.0-7.3 million tonnes, revised down from 7.2-7.6 million tonnes.

UPDATE: Mosaic Company Revises Outlook: Sees Q2 Phosphate Sales Volume At 1.5–1.6M Tonnes, Down From 1.7M–1.9M Prior; FY25 Output Trimmed To 7.0M–7.3M Tonnes Vs 7.2M-7.6M Tonnes Prior

RYVYL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) ("RYVYL" or the "Company"), a leading innovator of payment transaction solutions leveraging electronic payment technology, announced the securityholder of its remaining 8% Senior Convertible Note ("Note"), has converted the entire outstanding principal balance of $4.0 million and accrued interest of $136,000 into 7.1 million shares of common stock.

RVYL

RYVYL's Securityholder Converts Final $4M Senior Note, Including $136K Interest, Into 7.1M Shares

Manchester United Q3 2025 Adj. EPS $(0.04) May Not Be Comparable To $(0.33) Estimate, Sales $207.26M Beat $202.47M Estimate

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Constellation Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)</h3>
<ul class="wp-block-list">
<li>On June 2, Constellation Brands announced delivery of notices of redemption for 4.75% senior notes due 2025 and 5.00% senior notes due 2026. The company's stock fell around 9% over the past month and has a 52-week low of $160.46.</li>
<li>RSI Value: 26.8</li>
<li>STZ Price Action: Shares of Constellation fell 3.6% to close at $170.60 on Thursday.</li>
<li>Edge Stock Ratings: 18.63 Momentum score with Value at 14.10. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/STZ"><img loading="lazy" decoding="async" width="441" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071110/image-87.png" alt="" class="wp-image-941078" style="width:325px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071110/image-87.png 441w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071110/image-87-300x124.png 300w" sizes="(max-width: 441px) 100vw, 441px" /></a></figure>
<h3 class="wp-block-heading">Coca-Cola Consolidated Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>)</h3>
<ul class="wp-block-list">
<li>On May 15, Coca-Cola Consolidated announced a $90 million investment in Columbus facility. &#8220;The investment we&#8217;ve made here in Columbus is evidence of our focus on growth in Columbus,&#8221; said Sam Meiner, VP, Mid-West Market Unit at Coca-Cola Consolidated. &#8220;This commitment to our teammates and production capabilities is a long-term dedication to improving how we serve the world&#8217;s best brands and flavors to our communities and the people of Ohio.&#8221; The company's stock fell around 10% over the past month and <a href="https://www.benzinga.com/quote/COKE">has a 52-week low</a> of $96.60.</li>
<li>RSI Value: 25.8</li>
<li>COKE Price Action: Shares of Coca-Cola Consolidated fell 1.4% to close at $106.17 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606">COKE stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606"><img loading="lazy" decoding="async" width="927" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88.png" alt="" class="wp-image-941079" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88-768x705.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">Diageo PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>)</h3>
<ul class="wp-block-list">
<li>On May 19, Diageo reported a third-quarter fiscal 2025 trading update that showed steady growth in organic net sales and progress on its operational transformation efforts. The maker of Smirnoff and Guinness posted $4.4 billion in net sales for the quarter ended March 31, marking a 2.9% increase year-over-year. Organic net sales rose 5.9%, driven by stronger pricing and shipment volumes. The company's stock fell around 8% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/DEO">low of $100.72.</a></li>
<li>RSI Value: 29</li>
<li>DEO Ltd Price Action: Shares of Diageo fell 5.1% to close at $105.20 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606">DEO shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606"><img loading="lazy" decoding="async" width="862" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89.png" alt="" class="wp-image-941080" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89.png 862w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89-300x290.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89-768x741.png 768w" sizes="(max-width: 862px) 100vw, 862px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

COKE

Top 3 Risk Off Stocks That Could Blast Off This Month

Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and maintains $24 price target.

CLBT

Needham Reiterates Buy on Cellebrite DI, Maintains $24 Price Target

Fury Gold Mines Limited (NYSE:<a href="https://www.benzinga.com/stock/FURY#NYSE">FURY</a>) ("Fury" or the "Company") announces that the proposed private placement offering announced June 5, 2025 has been increased from C$2,500,000 to C$3,080,000. Fury now intends to privately place with a small group of accredited and institutional investors in Canada a total of 4,000,000 flow-through common shares (the "Shares") of the Company, at a price of C$0.77 per Share for total gross proceeds of C$3,080,000 (the "Offering"). This offering figure could increase by up to approximately 15.4% if a strategic investor elects to exercise its pre-emptive participation rights disclosed in a <a href="https://www.globenewswire.com/Tracker?data=HQaYc8Cgq_iu2dRsUPGUu4P8s3eHB2eh9WbW-ZLoEWjXoCqjvRLyTfYk3hp6kqzAmBb84_tbBVoR_n5MFK0Ixq9Z6MdXWXYjmhnHy6AtbvrgY_wLYJ1ItwqiqvhkOwikomCI1oUBmQMZQ53iXZrkOtyfCPzsDPY_b__Zik8XVFI=">May 27, 2025 news release</a>.
The Offering is expected to close on or about June 19, 2025 (the "Closing Date"), subject to execution of subscription agreements and customary closing conditions, including receipt of all necessary approvals, including the approval of the Toronto Stock Exchange ("TSX") and the NYSE American LLC. Other previously announced terms and conditions remain the same.

FURY

Fury Gold Mines Increases Proposed Private Placement Offering From C$2.50M To C$3.08M

G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is looking for Q2 Adj EPS of $0.02-$0.12 vs $0.48 analyst estimate. Q2 Revenue expected to be more than $570.00M vs $621.00M Est

GIII

G-III Apparel Group Sees Q2 EPS $0.02-$0.12; Q2  Revenue Expected To Be Approximately $570.00M vs $621.00M Est

PRPH

ProPhase Labs Forms Clinical Science Advisory Board To Support Clinical Adoption And Commercialization Of Breakthrough BE-Smart Molecular Test For Esophageal Disease

D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy and maintains $19 price target.

RCEL

D. Boral Capital Maintains Buy on AVITA Medical, Maintains $19 Price Target

Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) (the "Company" or "Sandisk") announced today the pricing of a secondary public offering (the "Offering") of 18,534,581 shares of its common stock (the "SNDK Shares") currently owned by Western Digital Corporation, the Company's former parent ("WDC"). The size of the offering reflects an increase from the 17,000,000 shares of common stock originally proposed to be sold. The SNDK Shares will be offered at a public offering price of $38.50 per share. Sandisk is not selling any shares of common stock and will not receive any proceeds from the sale of the SNDK Shares in the Offering or from the debt-for-equity exchange.

SNDK

Sandisk Announces Pricing For Expanded Secondary Offering; WDC to Sell 18.5M Shares, Priced at $38.50/Shr

Press Releases

Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Management

NAYA Biosciences Announces Nomination of New Board Members

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Comments

Black Diamond Therapeutic

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL